October 2003
10th Conference on Retroviruses and Opportunistic Infections
-
Phase III, 48-Week NEAT
Study Results Comparing GW433908 (908) to Nelfinavir
(February 13, 2003)
News Release
-
24-Week Data
From the CONTEXT Trial Comparing GW433908/Ritonavir QD and BID to
Lopinavir/Ritonavir BID in Treatment-Experienced Patients
(February 13,
2003)
News Release
-
48-Week Resistance Data Comparing GW433908, Boosted and
Unboosted, With Nelfinavir
in Treatment-Naive HIV+ Patients
(February 10, 2003)
News Release
-
The Context Study: Efficacy and Safety of GW433908/RTV in PI-experienced
Subjects with
Virological Failure (24 Week Results)
E DeJesus, A LaMarca, M Sension, et al
Abstract
-
The NEAT Study: GW433908 Efficacy and Safety in ART-naïve Subjects, Final
48-week
Analysis
J Nadler, A Rodriguez-French, J Millard, P
Wannamaker
Abstract
-
GW433908 in ART-naive Subjects: Absence of Resistance at 48 Weeks with Boosted
Regimen and APV-like Resistance Profile with Unboosted Regimen
S Macmanus, PYates, S White, et al.
Abstract
|
|
|
New
and Noteworthy
ARV
Drugs Main Page
are in Portable Document
Format (PDF) and
require the
Adobe Acrobat Reader 5.
Some of these documents may take a few
minutes to
download.